

## **POSTER PRESENTATION**

Open Access

# Characterisation of a novel vaccine delivery system for livestock

Rebecca K. McLean<sup>1,2\*</sup>, Ann R. Wood<sup>1</sup>, Jayne C. Hope<sup>2</sup>, Gary Entrican<sup>1</sup>, David J. Griffiths<sup>1</sup>

From 1st Annual Meeting of the Scottish Society of Cytomics (SCC) 2014. "Translational Cytometry from Bench to Bedside"

Aberdeen, UK. 25 September 2014

### **Background**

Healthy animals perform better than those that are diseased; therefore there are significant benefits from preventing disease on farm by investigating new vaccine delivery systems. Recently, viral vectors have risen to prominence as candidates for generating immune responses. Of these viral candidates, lentiviruses are attractive as they have the ability to transduce non-dividing antigen presenting cells. For example, lentiviral vectors have been shown to produce an antigenmediated immune response in mice, providing long term, sterile protection against Malaria[1].

#### Material and methods

Transformed human embryonic kidney (293T) cells were transfected with four plasmids which encode the various vector components for the production of lentiviral vectors. Vectors produced so far contain an eGFP reporter cassette to facilitate measurement of infectivity by flow cytometry. Self-inactivating (SIN) vectors have been produced to decrease the probability of the generation of replication-competent virus[2]. To produce a SIN vector, viral enhancers and promoter sequences were deleted by Gibson Cloning leaving expression of transgenes controlled by an internal promoter. Integrase deficient lentiviral vectors were produced by introducing point mutations by PCR on the D,D-35-E motif within the integrase protein to reduce insertional oncogenesis[3].

#### Results

Stable expression of antigens is important to a successful vaccine, therefore the stability of ovine lentiviral

transduction was evaluated over a 4 week period with eGFP-positive cells measured periodically. 50% of cells remained eGFP-positive after 4 weeks in rapidly dividing cells suggesting a sustained, stable transduction. Ovine lentivirus vectors have the ability to infect a wide range of cell types from different species with similar efficiency to the well characterised murine leukaemia virus (MLV) vector. Self-inactivating vectors with non-active LTRs retain the ability to express transgenes *in vitro*. Integration deficient vectors appear to have to correct phenotype as eGFP-positive cells decreased over time in dividing cells.

#### **Conclusion**

We have created a novel, self-inactivating, integration deficient ovine lentiviral vector which retains the ability to express transgenes *in vitro*. Future studies will investigate ovine lentiviral vectors mechanisms of immune response *in vitro* and study their efficiency to deliver appropriate immunity *in vivo*.

#### Acknowledgements

This project is funded by Moredun Scientific and the Scottish Government.

#### Authors' details

<sup>1</sup>Moredun Research Institute, Pentlands Science Park, Edinburgh, EH26 0PZ, UK. \*. <sup>2</sup>Royal (Dick) School of Veterinary Science, University of Edinburgh, EH25 9RG, UK.

Published: 16 April 2015

#### References

- Coutant F, David RYS: A nonintegrative lentiviral vector-based vaccine provides long-term sterile protection against Malaria. PLoS One 2012, 7: e48644.
- Zufferey R, Dull T: Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol 1998, 72:9873-9880.
- Gaur M, Leavitt AD: Mutations in the human immunodeficiency virus type 1 integrase D,D(35)E motif do not eliminate provirus formation. J. Virol 1998. 72:4678-4685.

Full list of author information is available at the end of the article



<sup>\*</sup> Correspondence: Rebecca.McLean@moredun.ac.uk

Moredun Research Institute, Pentlands Science Park, Edinburgh, EH26 0PZ,

doi:10.1186/1476-9255-12-S1-P3

Cite this article as: McLean et al.: Characterisation of a novel vaccine delivery system for livestock. Journal of Inflammation 2015 12(Suppl 1):P3.

# Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

